Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs.
Fujiki F, Morimoto S, Nishida Y, Tanii S, Aoyama N, Inatome M, Inoue K, Katsuhara A, Nakajima H, Nakata J, Nishida S, Tsuboi A, Oka Y, Oji Y, Sogo S, Sugiyama H. Fujiki F, et al. Cancer Immunol Immunother. 2023 Jul;72(7):2347-2356. doi: 10.1007/s00262-023-03420-8. Epub 2023 Mar 20. Cancer Immunol Immunother. 2023. PMID: 36939853 Free PMC article.
Functional human Th17 clones with WT1-specific helper activity.
Tachino S, Fujiki F, Oka Y, Tsuboi A, Morimoto S, Lin YH, Tamanaka T, Kondo K, Nakajima H, Nishida S, Hosen N, Oji Y, Kumanogoh A, Sugiyama H. Tachino S, et al. Among authors: fujiki f. Cancer Immunol Immunother. 2013 Apr;62(4):801-10. doi: 10.1007/s00262-012-1385-3. Epub 2012 Dec 29. Cancer Immunol Immunother. 2013. PMID: 23275045 Free PMC article.
Two distinct effector memory cell populations of WT1 (Wilms' tumor gene 1)-specific cytotoxic T lymphocytes in acute myeloid leukemia patients.
Nakae Y, Oka Y, Fujiki F, Morimoto S, Kamiya T, Takashima S, Nakata J, Nishida S, Nakajima H, Hosen N, Tsuboi A, Kyo T, Oji Y, Mizuguchi K, Kumanogoh A, Sugiyama H. Nakae Y, et al. Among authors: fujiki f. Cancer Immunol Immunother. 2015 Jul;64(7):791-804. doi: 10.1007/s00262-015-1683-7. Epub 2015 Apr 3. Cancer Immunol Immunother. 2015. PMID: 25835542 Free PMC article.
Establishment of a novel platform cell line for efficient and precise evaluation of T cell receptor functional avidity.
Morimoto S, Fujiki F, Kondo K, Nakajima H, Kobayashi Y, Inatome M, Aoyama N, Nishida Y, Tsuboi A, Oka Y, Nishida S, Nakata J, Hosen N, Oji Y, Sugiyama H. Morimoto S, et al. Among authors: fujiki f. Oncotarget. 2018 Sep 25;9(75):34132-34141. doi: 10.18632/oncotarget.26139. eCollection 2018 Sep 25. Oncotarget. 2018. PMID: 30344927 Free PMC article.
A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma.
Tsuboi A, Hashimoto N, Fujiki F, Morimoto S, Kagawa N, Nakajima H, Hosen N, Nishida S, Nakata J, Morita S, Sakamoto J, Oji Y, Oka Y, Sugiyama H. Tsuboi A, et al. Among authors: fujiki f. Cancer Immunol Immunother. 2019 Feb;68(2):331-340. doi: 10.1007/s00262-018-2274-1. Epub 2018 Nov 14. Cancer Immunol Immunother. 2019. PMID: 30430205 Free PMC article. Clinical Trial.
Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides.
Fujiki F, Tsuboi A, Morimoto S, Hashimoto N, Inatome M, Nakajima H, Nakata J, Nishida S, Hasegawa K, Hosen N, Oka Y, Oji Y, Sogo S, Sugiyama H. Fujiki F, et al. Cancer Immunol Immunother. 2021 Jan;70(1):253-263. doi: 10.1007/s00262-020-02675-9. Epub 2020 Jul 22. Cancer Immunol Immunother. 2021. PMID: 32696072 Free PMC article.
Identification of mouse helper epitopes for WT1-specific CD4+ T cells.
Nakajima H, Nakata J, Imafuku K, Hayashibara H, Isokawa K, Udaka K, Fujiki F, Morimoto S, Hasegawa K, Hosen N, Hashii Y, Nishida S, Tsuboi A, Oka Y, Oji Y, Sogo S, Sugiyama H. Nakajima H, et al. Among authors: fujiki f. Cancer Immunol Immunother. 2021 Nov;70(11):3323-3335. doi: 10.1007/s00262-021-03003-5. Epub 2021 Jul 16. Cancer Immunol Immunother. 2021. PMID: 34272593 Free PMC article.
WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone.
Nakajima H, Kawasaki K, Oka Y, Tsuboi A, Kawakami M, Ikegame K, Hoshida Y, Fujiki F, Nakano A, Masuda T, Wu F, Taniguchi Y, Yoshihara S, Elisseeva OA, Oji Y, Ogawa H, Azuma I, Kawase I, Aozasa K, Sugiyama H. Nakajima H, et al. Among authors: fujiki f. Cancer Immunol Immunother. 2004 Jul;53(7):617-24. doi: 10.1007/s00262-003-0498-0. Epub 2004 Feb 7. Cancer Immunol Immunother. 2004. PMID: 15175906 Free PMC article.
Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
Fujiki F, Oka Y, Tsuboi A, Kawakami M, Kawakatsu M, Nakajima H, Elisseeva OA, Harada Y, Ito K, Li Z, Tatsumi N, Sakaguchi N, Fujioka T, Masuda T, Yasukawa M, Udaka K, Kawase I, Oji Y, Sugiyama H. Fujiki F, et al. J Immunother. 2007 Apr;30(3):282-93. doi: 10.1097/01.cji.0000211337.91513.94. J Immunother. 2007. PMID: 17414319
Identification of a WT1 protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitope.
Li Z, Oka Y, Tsuboi A, Fujiki F, Harada Y, Nakajima H, Masuda T, Fukuda Y, Kawakatsu M, Morimoto S, Katagiri T, Tatsumi N, Hosen N, Shirakata T, Nishida S, Kawakami Y, Udaka K, Kawase I, Oji Y, Sugiyama H. Li Z, et al. Among authors: fujiki f. Microbiol Immunol. 2008 Nov;52(11):551-8. doi: 10.1111/j.1348-0421.2008.00069.x. Microbiol Immunol. 2008. PMID: 19090835 Free article.
81 results